<DOC>
	<DOC>NCT00185757</DOC>
	<brief_summary>The purpose of the study is to determine if the use of activated T cells can effectively treat relapsed disease following allogeneic hematopoietic cell transplantation without causing GVHD.</brief_summary>
	<brief_title>Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<criteria>Evidence of recurrent or persistent hematologic malignancy following HLA matched allogeneic hematopoietic cell transplant eligible for DLI no evidence of GVHD stable immunosuppressive regimen adequate renal and liver function CML patients who have not received DLI, active infections</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>